Zhaoke Ophthalmology Limited (6622.HK)
6622.HK Stock Price Chart
Explore Zhaoke Ophthalmology Limited interactive price chart. Choose custom timeframes to analyze 6622.HK price movements and trends.
6622.HK Company Profile
Discover essential business fundamentals and corporate details for Zhaoke Ophthalmology Limited (6622.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Apr 2021
Employees
294.00
Website
https://www.zkoph.comCEO
Xiaoyi Li
Description
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
6622.HK Financial Timeline
Browse a chronological timeline of Zhaoke Ophthalmology Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 24 Mar 2025
EPS came in at -$0.16 surpassing the estimated -$0.42 by +60.54%, while revenue for the quarter reached $10.82M , missing expectations by -41.86%.
Earnings released on 31 Dec 2024
EPS came in at -$0.16 , while revenue for the quarter reached $10.40M .
Earnings released on 29 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.37 by +79.60%, while revenue for the quarter reached $26.72M , beating expectations by +113.37%.
Earnings released on 24 May 2024
EPS came in at -$0.08 , while revenue for the quarter reached $26.92M .
Earnings released on 27 Mar 2024
EPS came in at -$0.15 surpassing the estimated -$0.56 by +72.58%, while revenue for the quarter reached $4.12M , missing expectations by -97.01%.
Earnings released on 20 Mar 2024
EPS came in at -$0.15 , while revenue for the quarter reached $3.99M .
Earnings released on 23 Aug 2023
EPS came in at -$0.25 surpassing the estimated -$0.44 by +44.63%, while revenue for the quarter reached $6.45M , beating expectations by +149.17%.
Earnings released on 30 Jun 2023
EPS came in at -$0.23 , while revenue for the quarter reached $6.11M .
Earnings released on 27 Mar 2023
EPS came in at -$0.25 surpassing the estimated -$0.45 by +44.92%.
Earnings released on 31 Dec 2022
EPS came in at -$0.26 .
Earnings released on 24 Aug 2022
EPS came in at -$0.18 surpassing the estimated -$0.52 by +64.48%.
Earnings released on 30 Jun 2022
EPS came in at -$0.17 .
Earnings released on 31 Dec 2021
EPS came in at -$0.16 .
Earnings released on 30 Sept 2021
EPS came in at -$0.16 surpassing the estimated -$0.43 by +63.15%.
Earnings released on 30 Jun 2021
EPS came in at -$4.21 .
Earnings released on 31 Mar 2021
EPS came in at -$4.15 falling short of the estimated -$0.29 by -1.34K%.
Earnings released on 31 Dec 2020
EPS came in at -$1.19 .
6622.HK Stock Performance
Access detailed 6622.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.